Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Long-Term Debt Issuances (2019 - 2025)

BioNexus Gene Lab's Long-Term Debt Issuances history spans 5 years, with the latest figure at $15528.0 for Q1 2025.

  • For Q1 2025, Long-Term Debt Issuances fell 24.06% year-over-year to $15528.0; the TTM value through Mar 2025 reached $29979.0, up 291.63%, while the annual FY2024 figure was $78835.0, 94.42% down from the prior year.
  • Long-Term Debt Issuances for Q1 2025 was $15528.0 at BioNexus Gene Lab, down from $20448.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $20448.0 in Q1 2024 and bottomed at -$8550.0 in Q1 2021.
  • The 3-year median for Long-Term Debt Issuances is -$5997.0 (2021), against an average of $2926.6.
  • The largest annual shift saw Long-Term Debt Issuances plummeted 418.99% in 2021 before it dropped 24.06% in 2025.
  • A 3-year view of Long-Term Debt Issuances shows it stood at -$5997.0 in 2021, then skyrocketed by 440.97% to $20448.0 in 2024, then decreased by 24.06% to $15528.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Long-Term Debt Issuances are $15528.0 (Q1 2025), $20448.0 (Q1 2024), and -$5997.0 (Q3 2021).